Press Releases
August 2, 2022
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Aug. 2, 2022-- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive
June 22, 2022
In this Retrospective Matched Case Control Study, Belzupacap Sarotalocan Achieved Statistically Significant Vision Preservation Compared to Plaque Radiotherapy, the Current Standard of Care CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jun. 22, 2022-- Aura Biosciences Inc.
May 25, 2022
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 25, 2022-- Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that members of its executive team will
May 3, 2022
CAMBRIDGE, Mass. --(BUSINESS WIRE)--May 3, 2022-- Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, today announced that Elisabet de los Pinos, PhD, Chief Executive
Displaying 11 - 20 of 27